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rectal cancer (CRC) after controlling for other risk factors. METHODS: We identified a 
cohort of 37,044 elderly Medicare beneficiaries with incident CRC between 2003 and 
2009 who had colorectal surgery using the SEER-linked Medicare database. T2DM was 
identified using the ICD-9-CM (International Classification of Diseases, 9th Revision, 
and Clinical Modification) codes during the 12-months prior to incident diagnosis 
of CRC. CRC surgery was identified with procedure codes for colon resection, rectal 
resection, and other operations on the intestine including colostomy and ileostomy. If 
individuals with CRC had ICD-9-CM codes indicative of bowel perforation, peritonitis, 
or obstruction, they were considered to have emergency surgery. Chi-square tests 
and logistic regression were used to analyze the association between pre-existing 
T2DMand emergency surgery after adjustments for sex, race/ethnicity, age, cancer 
site, stage, region, and office visits in the 12 months prior to incident cancer. RESULTS: 
Unadjusted rates of emergency surgery were significantly lower among CRC patients 
with pre-existing T2DM compared to CRC patients without diabetes (9.8% vs.11.4%). 
This association, however, was not significant in adjusted analyses. CRC patients 
with highest number of annual office visits were significantly less likely than CRC 
patients with lowest number of annual office visits to receive emergency surgery 
(AOR= 0.69; 95%CI= 0.61, 0.78). Other risk factors for emergency surgery in CRC patients 
were old age (80-84 years: AOR= 1.15, 95%CI= 1.03, 1.29; 85 years and above: AOR= 1.41, 
95%CI= 1.26, 1.58), and late stage at diagnosis (regional stage: AOR= 2.14, 95%CI= 1.99, 
2.31; distant stage: AOR= 2.78, 95%CI= 2.54, 3.05). CRC patients with atherosclerosis 
were less likely to have emergency surgery compared to those without atherosclerosis 
(AOR= 0.89; 95%CI= 0.82, 0.97). CONCLUSIONS: Pre-existing T2DM was not associated 
with emergency surgery after controlling for a comprehensive list of risk factors.
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OBJECTIVES: NCCN guidelines recommend that non-metastatic colorectal cancer 
(CRC) patients receive a comprehensive work-up including detailed imaging studies. 
The purpose of this study was to evaluate physician concordance to NCCN guide-
lines in terms of the receipt of tests and procedures during the 6-month period prior 
to a patient’s CRC diagnosis. METHODS: A large integrated claims database span-
ning January 2008 to September 2013 was used to identify patients ≥ 50 years old 
diagnosed and treated for CRC. Patients were required to be continuously enrolled 
for ≥ 6 months pre- (baseline period) and ≥ 3 months post-diagnosis. Eligible patients 
were stratified into cohorts based on the occurrence and timing of metastatic (M) 
disease: no metastases (NM), ≤ 90 days (M1), and ≥ 90 days (M2) from initial diag-
nosis. Tests evaluated included disease-appropriate CT or MRI, ultrasound, blood 
and fecal screenings, baseline biopsy, CEA, endoscopy, PET-CT, proctoscopy, sig-
moidoscopy, and colonoscopy. RESULTS: There were 15,182 patients meeting study 
criteria, with 77.8% being NM, 11.2% M1, and 11.0% M2. Over 75% of patients had a 
health physical in the baseline period but only 43.3% received fecal or blood-based 
screenings. The most common invasive procedure was colonoscopy, occurring in 
9.6% of M1, 13.7% of M2, and 11.7% of NM patients. Less than 20% of NM patients 
(17.8%) received a chest, abdominal, or pelvic CT or MRI compared to 20.7% of M1 
and 33.8% of M2 patients. Twice as many M2 patients (30.9%) received a CEA test 
compared to 15.1% of M1 and 24.6% of NM patients. Biopsy, ultrasound (including 
endorectal), proctoscopy, and sigmoidoscopy were documented in less than 5% of 
all patients. CONCLUSIONS: In this population of CRC patients, concordance to 
NCCN guidelines was low, with NM patients receiving a lesser degree of complete 
work-up per guidelines compared with M patients.
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OBJECTIVES: While cancer registries such as SEER currently serve as the larg-
est source of cancer epidemiology, recent research (Cogle, et al., 2012) has sug-
gested that these registries may be underreporting AML due to methodological 
limitations. Using a claims-based algorithm, we estimated the incidence of acute 
myeloid leukemia (AML) in the < 65 year-old US population. METHODS: A retro-
spective analysis of claims was performed using 2010-2012 IMS Health LifeLink 
PharMetrics Plus (LifeLink), a longitudinal medical claims dataset comprised of 
adjudicated claims of > 150 million unique enrollees. LifeLink is representative of 
the US commercially-insured population aged ≤ 65. AML diagnoses were identified 
using ICD-9 codes and AML treatments were identified using CPT/HCPCS codes 
and ICD-9-CM infusion codes. Patients with ≥ 2 claims including AML diagnoses 
codes OR one AML medical claim and one AML treatment in 2012 were defined as 
prevalent AML patients. A sub-population of all prevalent AML patients without 
historical AML diagnoses or treatments during the prior two years were identified 
as new (incident) AML patients. Results were stratified by gender and age (< 18, 
18-39, 40-49, 50-59, 60-64 years). RESULTS: The overall 2012 incidence of the < 65 
population was 5.4 per 100,000 (95% CI: 5.2, 5.6), with incidence incrementally 
increasing with age (i.e., lowest in the < 18 cohort [3.2 per 100,000] and highest in 
the 60-64 cohort [12.3 per 100,000]). Incidence among males was slightly higher 
than among females, 5.7 (95% CI: 5.3, 6.0) and 5.2 (95% CI: 4.9, 5.5) per 100,000, 
respectively. Males 60-64 had the highest incidence rate, 13.5 per 100,000 (95% CI: 
11.7, 15.2). CONCLUSIONS: Our 2012 AML incidence estimates are substantially 
higher than published SEER estimates for the < 65 population: 5.4 per 100,000 vs. 
SEER’s 1.8 per 100,000, respectively. Thus, the current AML burden of disease may 
be underestimated, further justifying the need for earlier detection and more 
efficacious treatment options.
ethnicity disparities exist in the association between diabetes and pancreatic can-
cer. METHODS: In a retrospective cross-sectional study, community-dwelling and 
institutionalized Medicare beneficiaries aged 65 or over without health maintenance 
organization enrollment from the Medicare Current Beneficiary Survey (MCBS) from 
2001 to 2010 were included. The outcome of the study was pancreatic cancer; and the 
key explanatory variables were diabetes and race/ethnicity. Potential confounders 
considered included age, gender, education, marital status, income, residence area, 
body mass index (BMI), smoking status, Charlson comorbidity index (CCI), and use 
of preventive services. The International Classification of Diseases-9 codes were 
used to identify the outcome and explanatory variables from the Medicare Part 
A and B claims. Logistic regressions were performed to estimate the association 
between diabetes and pancreatic cancer. RESULTS: A total of 98,966 person-years 
of elderly Medicare beneficiaries were included in the analysis. After controlling 
for potential confounders, the association between diabetes and pancreatic can-
cer was statistically significant (odds ratio [OR], 3.15; 95% confidence interval [CI], 
2.07-4.77). Compared to non-Hispanic whites, non-Hispanic blacks (OR, 0.43; 95% CI, 
0.15-1.20) and Hispanics (OR, 0.78; 95% CI, 0.33-1.85) had similar risks of pancreatic 
cancer. CONCLUSIONS: This study found that diabetes is associated with pancreatic 
cancer in the elderly Medicare population. However, racial/ethnicity differences do 
not explain the association between diabetes and pancreatic cancer.
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OBJECTIVES: The burden of comorbid illness is known to be higher among lung cancer 
patients and it’s also shown to impact survival outcomes. However, the influence of 
comorbidity on in-hospital surgical outcomes among lung cancer patients remains 
unknown. Therefore, this study examined the effect of comorbidity on risk of post-
operative complications, prolonged hospitalization, and in-patient death among lung 
cancer patients following surgery. METHODS: A retrospective analysis of hospital 
discharge data from the 2011 Health Care Utilization Project - Nationwide Inpatient 
Sample (HCUP-NIS) database was performed. Discharges of patients who underwent 
surgery for lung cancer during 2011 were identified. Information about patients and 
hospitals characteristics were obtained. Comorbidities were identified and used to 
calculate Charlson comorbidity index score. Patients were then divided based on these 
scores into four groups: 0, 1, 2, and ≥ 3. Multivariate logistic regression analyses was 
used to examine risk adjusted association between comorbidity score and the study 
outcomes. RESULTS: We identified 19,564 patients’ discharges that meet our inclusion 
criteria. Compared to patients with no comorbid conditions, patients with one or more 
comorbid conditions saw a two-fold increase in the risk of post-operative complica-
tions (p< 0.001). The risk of prolonged hospitalization was also higher among patients 
with a comorbidity score of 1, 2, or ≥ 3, compared to patients with a comorbidity score 
of zero (p< 0.001). Higher comorbidity burden also increased the risk of in-patient 
death by three folds (p< 0.001). CONCLUSIONS: In-hospital outcomes among lung 
cancer patients following surgery are negatively impacted by presence of comorbid 
illness. Post-operative morbidity and mortality among these patients may be reduced 
if their comorbid conditions are managed effectively.
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OBJECTIVES: Some new cancer therapies are associated with prolonged patient 
survival; therefore, management of chronic comorbidities in cancer patients has 
become more important. We sought to measure the prevalence of lipid disorders, 
and other chronic comorbidities, among cancer patients admitted to U.S. hospitals 
over a 14-year period. METHODS: We utilized data from the U.S. National Hospital 
Discharge Surveys from 1996 to 2009. We limited the study to patients ≥ 18 years 
of age with a primary discharge diagnosis of lung, breast, prostate, or colorectal 
cancer (ICD-9-CM codes 162, 174, 185, and 153, respectively). Data weights were 
used to derive national estimates. The prevalence of diabetes (250), ischemic heart 
disease (410-414), heart failure (428), cerebrovascular disease (430-438), and lipid 
disorders (272) was calculated for each year and cancer type. RESULTS: Roughly 
6 million visits were represented over the 14-year study period (lung 2.1, breast 
1.3, prostate 1.3, and colorectal cancer 1.6 million). One-third of patients admit-
ted with cancer had at least one comorbidity, and 8% had at least two comor-
bidities over the entire 14-year study interval; however, the rates of comorbidity 
changed drastically over time—particularly for lipid disorders. Of the patients 
admitted with lung cancer in 1996, only 2% had lipid disorders, compared to 13% 
in 2009. Similar patterns were observed for those patients admitted with breast 
cancer (2% to 17%), prostate cancer (3% to 30%), and colorectal cancer (2% to 12%). 
Prevalence of diabetes and ischemic heart disease also increased, but to a lesser 
extent. CONCLUSIONS: Management of lipid disorders in patients with cancer 
has become increasingly important. U.S. studies focused on improving cancer 
mortality, as well as the rising costs of care, should increasingly take chronic 
conditions—particularly lipid disorders—into account.
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OBJECTIVES: To examine the association between pre-existing Type 2 Diabetes Mellitus 
(T2DM) and risk of emergency colorectal surgery among elderly patients with colo-
